Ondansetron — Drug Intelligence | 23 EU Trials

Filter these 23 trials by condition, phase, country and more.

Open in Search →

23 Registered trials

11 Recruiting

11 Completed trials

19 Sponsors

22 Countries

Phase III

Phase II/III

Phase II

Phase IV

Phase III: 8 Phase II/III: 3 Phase II: 8 Phase I/II: 1 Phase IV: 3

Oversight events:

3 temporary halts 6 urgent safety measures across 2 trials

View oversight register →

Indications tested

Myelofibrosis 3 Thrombocytopenia 1 Colorectal cancer metastatic 1 Overweight 1 Rectal cancer stage III 1 Obesity 1 Rectal cancer stage II 1 HER2 positive breast cancer 1 Papillary serous endometrial carcinoma 1

Sponsors using this IMP

Karyopharm Therapeutics Inc. 4 K-Group Beta Inc. 2 Kartos Therapeutics Inc. 2 Umea University 2 Aarhus University Hospital 1 Acacia Pharma Limited 1 Assistance Publique Hopitaux De Paris 1 AstraZeneca AB 1 Eli Lilly Cork Limited 1 Fondazione Gimema Franco Mandelli Onlus 1 Helse Bergen HF 1 Helsinn Healthcare S.A. 1

All trials

23 total

Postoperative recovery with the addition of long-acting NK1- and 5-HT3 receptor antagonists as prophylaxis for post-operative nausea and vom… Pending

2025-522529-36-00 Phase III 1 country Region Vaesternorrland; Umea University
Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer Recruiting

2022-502983-19-00 Phase II 5 countries K-Group Beta Inc.
metastatic colorectal cancer Recruiting

2023-504831-42-00 Phase III 1 country Assistance Publique Hopitaux De Paris
An open-label, pharmacokinetic, safety, and efficacy study (Part I, single cycle) and double-blind, efficacy, non inferiority, and safety st… Recruiting

2024-514321-39-00 Phase II/III 3 countries Helsinn Healthcare S.A.
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Phase III 13 countries Kartos Therapeutics Inc.
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting

2024-511309-47-00 Phase II 13 countries Karyopharm Therapeutics Inc.
A Randomised study comparing Lutetium-177 versus Apalutamide/Enzalutamide/Abiraterone, in metastatic Hormon Sensitive Prostate Cancer in PSM… Recruiting

2022-500570-33-00 Phase III 1 country Region Västerbotten; Umea University
EASYlight study Recruiting

2023-508417-16-00 Phase IV 1 country Reinier de Graaf Groep
Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal canc… Recruiting

2023-506703-26-00 Phase III 1 country Institut Jules Bordet
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting

2022-501504-95-00 Phase II 3 countries Karolinska University Hospital
Acute Subcutaneous Semaglutide in Acute Ischemic Stroke (ASSET Trial) Recruiting

2022-501072-25-02 Phase II 1 country Aarhus University Hospital
Selinexor, Dexamethasone and Bortezomib in Patients with Multiple Myeloma Recruiting

2024-511608-18-00 Phase II 1 country Karyopharm Therapeutics Inc.
Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended

2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Phase III 13 countries Karyopharm Therapeutics Inc.
A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokine… Ended

2023-504215-32-00 Phase I/II 3 countries AstraZeneca AB
Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Diffuse Large B-Cell Lymphoma Ended

2024-513616-95-00 Phase II/III 3 countries Karyopharm Therapeutics Inc.
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended

2023-507324-23-00 Phase II 3 countries K-Group Beta Inc.
A study of intravenous amisulpride as prevention of post-operative nausea and vomiting in children Ended

2024-518778-15-00 Phase III 2 countries Acacia Pharma Limited
Experimental hypothermia using cold ambient temperature and drug-induced inhibition of shivering in awake, healthy volunteers: a crossover, … Ended

2023-506020-81-00 Phase II 1 country Helse Bergen HF
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Phase II/III 15 countries Kartos Therapeutics Inc.
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended

2022-500101-41-00 Phase IV 4 countries Eli Lilly Cork Limited
Clinical trial on Spinal Anaesthesia vs. General Anaesthesia (SAGA) on recovery after hip and knee replacements Ended

2022-501221-21-00 Phase IV 1 country Hvidovre Hospital
A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients with PK… Ended

2022-502932-37-00 Phase III 1 country Synlogic Inc.

Showing 1–23 of 23 trials

← All drugs A–Z